Skip to main content
S&P 5007,704.42+1.79%DOW53,294.00+2.91%NASDAQ25,872.07+1.97%BTC$80,555.00+3.65%ETH$2,432.98+5.91%GOLD$4,075.60+3.43%OIL$88.71-7.68%
Smart Investors Daily
SID Premium
ST

NASDAQ · STIM

Neuronetics, Inc.

Healthcare · Medical - Diagnostics & Research

$2.26

Up+$0.57 (+25.22%)

Updated Nov 4, 2026, 6:25 PM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
94.17M
P/E ratio
-2.1
Dividend yield
0.00%
52-week range
$0.80 – $3.44
Volume
1.83M
Avg. volume
1.57M

Price performance · STIM

STIM price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

STIM closed at $2.26 after 21 trading sessions, up 2.26% for the selected period.

Last close
$2.26
Period change
+2.26%
Period low
$1.89
Period high
$2.38
Daily close
View OHLC price history
STIM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$2.11$2.275$2.11$2.261.83M
Nov 2, 2026$2.34$2.37$2.035$2.06976.15K
Oct 30, 2026$2.34$2.3761$2.145$2.251.09M
Oct 29, 2026$2.27$2.48$2.235$2.38832.3K
Oct 28, 2026$2.18$2.285$2.175$2.26319.22K
Oct 27, 2026$2.24$2.25$2.18$2.19278.26K
Oct 26, 2026$2.13$2.35$2.11$2.241.1M
Oct 23, 2026$2.08$2.175$2.02$2.11600.45K
Oct 22, 2026$1.99$2.105$1.98$2.08788.22K
Oct 21, 2026$1.98$2.02$1.9645$2.01327.96K
Oct 20, 2026$1.88$2.02$1.8765$1.98603.22K
Oct 19, 2026$1.88$1.94$1.85$1.91559.15K
Oct 16, 2026$1.95$1.971$1.8501$1.885967.69K
Oct 15, 2026$1.88$1.99$1.84$1.95768.72K
Oct 14, 2026$1.95$1.97$1.88$1.885818.3K
Oct 13, 2026$2.13$2.135$1.99$1.99547.95K
Oct 12, 2026$2.13$2.14$2.10$2.13329.67K
Oct 9, 2026$2.14$2.20$2.11$2.13581.28K
Oct 8, 2026$2.192$2.192$2.105$2.14646.89K
Oct 7, 2026$2.21$2.225$2.15$2.17642.17K
Oct 6, 2026$2.22$2.28$2.19$2.21771.88K

Latest STIM news

The latest Smart Investors Daily articles mentioning STIM.

Stock researchCompany · Overview

STIM research

Overview

Company profile and research snapshot.

Company profile

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$8.00
Implied upside
—
Analysts
—
STIM recent ratings
DateFirmRatingTarget
Sep 17, 2026BTIGBuy—
Sep 11, 2026B. Riley SecuritiesBuy—
Sep 9, 2026BTIGBuy—
Aug 11, 2026BTIGBuy—
Jul 20, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call

MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release third quarter 2026 financial and operating results prior to market open on Wednesday, November 4, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the sa

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By